Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Cancer Epidemiology

Volumn 42, Issue , 2016, Pages 46-52

  Lang Kuhs, Krystle A ^a   Pawlita, Michael ^b   Gibson, Sandra P ^c   Schmitt, Nicole C ^c,d,e   Trivedi, Sumita ^c   Argiris, Athanassios ^f,g   Kreimer, Aimée R ^a   Ferris, Robert L ^c   Waterboer, Tim ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g HYGEIA HOSPITAL   (Greece)

Author keywords

HPV antibodies; HPV seropositivity; HPV16; HPV16 E6; Human papillomavirus 16; Non OPC; Non oropharyngeal cancer; OPC; Oropharyngeal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; HUMAN PAPILLOMAVIRUS TYPE 16 E1 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 E2 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 E4 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 E6 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 E7 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 L1 ANTIBODY; PROTEIN E6; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ONCOPROTEIN; REPRESSOR PROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MULTIMODALITY CANCER THERAPY; OROPHARYNX CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; EPIDEMIOLOGY; HEAD AND NECK TUMOR; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION;

HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84961786714     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.03.003     Document Type: Article

References (23)

1. Hocking J.S., Stein A., Conway E.L., et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br. J. Cancer 2011, 104(5):886-891.
2. Blomberg M., Nielsen A., Munk C., Kjaer S.K. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int. J. Cancer 2011, 129(3):733-741.
3. Reddy V.M., Cundall-Curry D., Bridger M.W. Trends in the incidence rates of tonsil and base of tongue cancer in England: 1985-2006. Ann. R. Coll. Surg. Engl. 2010, 92(8):655-659.
4. Syrjanen S. HPV infections and tonsillar carcinoma. J. Clin. Pathol. 2004, 57(5):449-455.
5. Ioka A., Tsukuma H., Ajiki W., Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn. J. Clin. Oncol. 2005, 35(1):45-47.
6. Braakhuis B.J., Visser O., Leemans C.R. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 2009, 45(9):e85-9.
7. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008, 26(4):612-619.
8. Gillison M.L., Alemany L., Snijders P.J., et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012, 30(Suppl. 5):F34-54.
9. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 2011, 29(32):4294-4301.
10. Kreimer A.R., Johansson M., Waterboer T., et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 2013, 31(21):2708-2715.
11. Ndiaye C., Mena M., Alemany L., et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014, 15(12):1319-1331.
12. Smith E.M., Rubenstein L.M., Haugen T.H., Pawlita M., Turek L.P. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J. Oncol. 2012, 2012:571862.
13. Lopez R.V., Levi J.E., Eluf-Neto J., et al. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. Cancer Causes Control 2014, 25(4):461-471.
14. Ribeiro K.B., Levi J.E., Pawlita M., et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int. J. Epidemiol. 2011, 40(2):489-502.
15. Anantharaman D., Gheit T., Waterboer T., et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J. Natl. Cancer Inst. 2013, 105(8):536-545.
16. Combes J.D., Franceschi S. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2014, 50(5):370-379.
17. Waterboer T., Sehr P., Pawlita M. Suppression of non-specific binding in serological Luminex assays. J. Immunol. Methods 2006, 309(1-2):200-204.
18. Waterboer T., Sehr P., Michael K.M., et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin. Chem. 2005, 51(10):1845-1853.
19. Sitas F., Egger S., Urban M.I., et al. InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J. Natl. Cancer Inst. 2012, 104(2):147-158.
20. Clifford G.M., Shin H.R., Oh J.K., et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan: south Korea. Cancer Epidemiol. Biomarkers Prev. 2007, 16(9):1874-1879.
21. Argiris A., Heron D.E., Smith R.P., et al. Induction docetaxel: cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J. Clin. Oncol. 2010, 28(36):5294-5300.
22. Singhi A.D., Westra W.H. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010, 116(9):2166-2173.
23. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010, 363(1):24-35.